Means Investment CO. Inc. Lowers Stake in CVS Health Corporation $CVS

Means Investment CO. Inc. lessened its stake in CVS Health Corporation (NYSE:CVS) by 65.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,111 shares of the pharmacy operator’s stock after selling 7,793 shares during the period. Means Investment CO. Inc.’s holdings in CVS Health were worth $326,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in CVS. Capital World Investors increased its holdings in CVS Health by 2.1% during the 3rd quarter. Capital World Investors now owns 68,382,158 shares of the pharmacy operator’s stock worth $5,155,380,000 after purchasing an additional 1,419,575 shares during the period. State Street Corp lifted its stake in CVS Health by 0.3% in the third quarter. State Street Corp now owns 58,938,286 shares of the pharmacy operator’s stock worth $4,443,357,000 after acquiring an additional 149,701 shares during the period. Capital International Investors grew its holdings in CVS Health by 1.1% during the 3rd quarter. Capital International Investors now owns 26,692,203 shares of the pharmacy operator’s stock worth $2,012,347,000 after acquiring an additional 302,499 shares in the last quarter. Invesco Ltd. increased its position in CVS Health by 3.2% during the 3rd quarter. Invesco Ltd. now owns 24,293,058 shares of the pharmacy operator’s stock valued at $1,831,454,000 after purchasing an additional 760,579 shares during the period. Finally, Capital Research Global Investors increased its position in CVS Health by 24.5% during the 3rd quarter. Capital Research Global Investors now owns 11,469,250 shares of the pharmacy operator’s stock valued at $864,667,000 after purchasing an additional 2,253,531 shares during the period. 80.66% of the stock is owned by hedge funds and other institutional investors.

Key CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Robert W. Baird raised its price target to $94 and rates CVS as “Outperform,” signaling analyst confidence in upside potential. Baird price target raise
• Positive Sentiment: CVS reached a proposed settlement with the FTC on insulin-related complaints, which management and some investors view as reducing a major regulatory overhang for the PBM business. FTC insulin settlement
• Positive Sentiment: Underlying fundamentals remain supportive: CVS reported a recent quarterly revenue and EPS beat and set FY?2026 EPS guidance, which provides a baseline for earnings-driven upside (management highlighted improving PBM, insurance and pharmacy cash flow).
• Neutral Sentiment: Consensus sentiment among brokers is generally favorable (average recommendation around “Moderate Buy”); median analyst price targets sit notably above the current price, implying multi?month upside if operational/ regulatory risks fade. Analyst ratings and targets
• Neutral Sentiment: CVS is attracting retail and research attention (trending on Zacks), which can amplify intraday moves but doesn’t itself change fundamentals. Zacks trending note
• Negative Sentiment: Renewed focus on PBM legal and regulatory risk is the main drag today — a proposed class action and broader federal scrutiny of PBM practices (specialty drug pricing, steering to affiliated pharmacies) are keeping headline risk elevated and prompting short?term profit-taking. PBM legal/regulatory overhang
• Negative Sentiment: An active shareholder proxy-access push (vote ahead of the May annual meeting) and related governance debate could distract management and add uncertainty to investor sentiment even as regulatory matters progress. Proxy access and governance clash

CVS Health Stock Performance

NYSE:CVS opened at $75.19 on Thursday. The company has a current ratio of 0.84, a quick ratio of 0.63 and a debt-to-equity ratio of 0.80. The company’s 50-day moving average price is $75.99 and its 200-day moving average price is $77.83. The company has a market cap of $96.37 billion, a P/E ratio of 54.49, a P/E/G ratio of 0.81 and a beta of 0.51. CVS Health Corporation has a twelve month low of $58.35 and a twelve month high of $85.15.

CVS Health (NYSE:CVS) last posted its earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share for the quarter, beating the consensus estimate of $1.00 by $0.09. The company had revenue of $105.69 billion for the quarter, compared to analyst estimates of $103.67 billion. CVS Health had a net margin of 0.44% and a return on equity of 11.31%. CVS Health’s revenue was up 8.2% on a year-over-year basis. During the same period in the previous year, the business posted $1.19 EPS. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. On average, sell-side analysts forecast that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, May 4th. Investors of record on Thursday, April 23rd will be paid a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a yield of 3.5%. The ex-dividend date of this dividend is Thursday, April 23rd. CVS Health’s payout ratio is presently 192.75%.

Wall Street Analyst Weigh In

CVS has been the subject of several research reports. TD Cowen reaffirmed a “buy” rating on shares of CVS Health in a research report on Friday, March 13th. Robert W. Baird boosted their price objective on shares of CVS Health from $92.00 to $94.00 and gave the stock an “outperform” rating in a research note on Wednesday. Sanford C. Bernstein upgraded CVS Health from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $91.00 to $94.00 in a report on Thursday, March 12th. Bank of America cut their price objective on shares of CVS Health from $100.00 to $95.00 and set a “buy” rating on the stock in a research report on Tuesday, January 27th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of CVS Health in a research report on Monday, December 29th. Twenty research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $95.05.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.